Close Menu

Cellectricon

Cellectricon is researching the spread of neurodegenerative disease-associated peptides that characterize Alzheimer's disease and Parkinson's disease.

NEW YORK (GenomeWeb News) – Cellectricon today said that it has signed agreement with two firms to distribute its products in Japan.

NEW YORK (GenomeWeb News) – Cellectricon and Fluxion Biosciences announced today they have settled a legal dispute dating back to 2009 in which Fluxion was accused of patent infringement.

Cellectricon has resumed an IP infringement suit it initially filed against Fluxion last summer.

The University of Lodz will use the system in its gene expression and screening projects.

BioFocus plans to use Cellectricon's Dynaflow automated patch clamp system for ion channel drug discovery.

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.